ARCHER 1050 study indicated that compared to gefitinib, dacomitinib showed a significant improvement in progression-free survival (PFS) in treating patients with EGFR-mutation-positive NSCLC (14.7 for dacomitinib vs. 9.2 months for gefitinib, hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.47 to 0.74; P < 0.0001), leading to the approval of dacomitinib as the new standard first-line treatment for patients with EGFR exon 19 deletion and L858R mutation positive NSCLC by China National Medical Products Administration in 2019 [7]. Here, EGFR is linked to non-small cell lung carcinoma.